Skip to main content
. 2020 Oct 22;7:550004. doi: 10.3389/fmed.2020.550004

Table 1.

Clinical characteristics of patients with SNV at initial diagnosis.

Total patients n = 2,660 Patient with TB n = 51 Patient without TB n = 2,609 P-value
Age, years 57.5 ± 16.9 59.1 ± 18.1 57.5 ± 16.8 0.502
Sex, n (%) 0.208
 Male 1,203 (45.2) 28 (54.9) 1,175 (45.0)
 Female 1,457 (54.8) 23 (45.1) 1,434 (55.0)
Diagnosis [ICD-10 code], n (%) 0.037
MPA 925 (34.8) 17 (33.3) 908 (34.8)
GPA 583 (21.9) 17 (33.3) 566 (21.7)
EGPA 593 (22.3) 4 (7.8) 589 (22.6)
PAN 559 (21.0) 13 (25.5) 546 (20.9)
Follow-up duration, years 3.3 ± 2.7 1.4 ± 2.0 3.3 ± 2.7 <0.001
Type of TB, n (%)
Pulmonary TB [A15, 16, 19] 43 (84.3) 43 (84.3)
Extrapulmonary TB [A17-18] 8 (15.7) 8 (15.7)
Insurance status, n (%) 1.000
 National Health Insurance 2,550 (95.9) 49 (96.1) 2,501 (95.9)
 Medical Aid 110 (4.1) 2 (3.9) 108 (4.1)
COMORBIDITIES [ICD-10 CODE], n (%)
Hypertension [I10-15] 1,255 (47.2) 27 (52.9) 1,228 (47.1) 0.490
Diabetes mellitus [E10-14] 899 (33.8) 19 (37.3) 880 (33.7) 0.706
Chronic kidney disease [N18] 349 (13.1) 11 (21.6) 338 (13.0) 0.111
Chronic obstructive pulmonary disease [J43-44] 427 (16.1) 9 (17.7) 418 (16.0) 0.904
HIV infection [B20-24] 0 (0.0) 0 (0.0) 0 (0.0) n/a
Silicosis [J62] 0 (0.0) 0 (0.0) 0 (0.0) n/a
IMMUNOSUPPRESSIVE AGENTS USAGE, n (%)
 Glucocorticoid usage ≥ 12 month 1,246 (46.8) 10 (19.6) 1,236 (47.4) <0.001
 Cyclophosphamide 1,153 (43.4) 18 (35.3) 1,135 (43.5) 0.304
 Azathioprine 992 (37.3) 10 (19.6) 982 (37.6) 0.013
 Methotrexate 433 (16.3) 7 (13.7) 426 (16.3) 0.759
 Rituximab 258 (9.7) 3 (5.9) 255 (9.8) 0.476

Values are expressed as mean (standard deviation) or in number (percentages).

SNV, systemic necrotizing vasculitides; TB, tuberculosis; ICD, international classification of diseases; MPA, microscopic polyangiitis; GPA, granulomatosis with polyangiitis; EGPA, eosinophilic granulomatosis with polyangiitis; PAN, polyarteritis nodosa; HIV, human immunodeficiency virus.